Advertisement

Tumor Biology

, Volume 35, Issue 9, pp 8875–8881 | Cite as

Decreased expression of IGFBP7 was a poor prognosis predictor for gastric cancer patients

  • Long Liu
  • Zhihui Yang
  • Weixing Zhang
  • Bing Yan
  • Qunhao Gu
  • Jianpeng Jiao
  • Xiaoqiang Yue
Research Article

Abstract

Increasing evidence indicated that insulin-like growth factor binding protein 7 (IGFBP7) was regarded as a potential tumor suppressor in various human cancers, but its role in gastric cancer is still largely unknown. In the present study, we performed a retrospective study which includes 247 gastric cancer patients. Among them, the IGFBP7 expression was detected by qRT-PCR in 138 cases of gastric cancer and adjacent non-tumor tissues and was further correlated with the expression of p53, Ki-67, and the clinicopathologic features. The results indicated that both IGFBP7 mRNA and protein in gastric cancer tissues were significantly lower than those in the adjacent non-tumor tissues. Additionally, the expression of IGFBP7 was correlated with the depth of invasion, lymph node metastasis, and TNM stage. Interestingly, the expression of IGFBP7 was negatively associated with Ki-67 (r = −0.227, P < 0.001) but positively associated with p53 (r = 0.140, P = 0.028). Univariate analysis showed that low expression of IGFBP7 was associated with poor prognosis (P < 0.001), and multivariate analysis showed that IGFBP7 (HR = 1.87; 95 % CI 1.65–2.17), distant metastasis (HR = 2.68; 95 % CI 1.58–4.56), and tumor size (HR = 1.45; 95 % CI 0.90–2.32) were independent prognostic factors for gastric cancer patients. These results demonstrated that IGFBP7 was downregulated in gastric cancer, and its low expression was potentially correlated with increased cancer cell proliferation and could be used to predicate poor prognosis in these patients.

Keywords

IGFBP7 Gastric cancer Prognosis Clinicopathological characteristics 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grants 81102693 and 81102565).

References

  1. 1.
    Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467–77.CrossRefPubMedGoogle Scholar
  2. 2.
    Lin Y, Ueda J, Kikuchi S, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17:4421–8.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Liu D, Zhang Z, Kong CZ. High FOXM1 expression was associated with bladder carcinogenesis. Tumour Biol. 2013;34:1131–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Hu BS, Hu H, Zhu CY, et al. Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol. 2013;34:515–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Sun DZ, Liu L, Jiao JP, et al. Syndrome characteristics of traditional Chinese medicine: summary of a clinical survey in 767 patients with gastric cancer. J Chin Integr Med. 2010;4:332–40.CrossRefGoogle Scholar
  6. 6.
    Wang WJ. Enhancing the treatment of metabolic syndrome with integrative medicine. J Chin Integr Med. 2013;11:153–6.CrossRefGoogle Scholar
  7. 7.
    Burger AM, Leyland-Jones B, Banerjee K, et al. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer. 2005;41:1515–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Wilson HM, Birnbaum RS, Poot M, et al. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ. 2002;13:205–13.PubMedGoogle Scholar
  9. 9.
    Walker GE, Antoniono RJ, Ross HJ, et al. Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBPrP1 and 25.1. Oncogene. 2006;25:1943–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Sato Y, Chen Z, Miyazaki K. Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/mac25. Cancer Sci. 2007;98:1055–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Wajapeyee N, Serra RW, Zhu X, et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132:363–74.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Suzuki H, Igarashi S, Nojima M, et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis. 2010;31:342–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Ruan W, Xu E, Xu F, et al. IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther. 2007;6:354–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Burger AM, Zhang X, Li H, et al. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene. 1998;16:2459–67.CrossRefPubMedGoogle Scholar
  15. 15.
    Landberg G, Ostlund H, Nielsen NH, et al. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Oncogene. 2001;20:3497–505.CrossRefPubMedGoogle Scholar
  16. 16.
    Tomimaru Y, Eguchi H, Wada H, et al. IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer. 2011;2:319–27.Google Scholar
  17. 17.
    Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2009. p. 117–26.Google Scholar
  18. 18.
    Sarela AI, Verbeke CS, Ramsdale J, et al. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002;86:886–92.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003;98:474–83.CrossRefPubMedGoogle Scholar
  20. 20.
    Yamasawa K, Nio Y, Dong M, et al. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res. 2002;8:2563–9.PubMedGoogle Scholar
  21. 21.
    Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:2846–50.CrossRefPubMedGoogle Scholar
  22. 22.
    Oh Y, Nagalla SR, Yamanaka Y, et al. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem. 1996;271:30322–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Yamanaka Y, Wilson EM, Rosenfeld RG, et al. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem. 1997;272:30729–34.CrossRefPubMedGoogle Scholar
  24. 24.
    Chen Y, Pacyna-Gengelbach M, Ye F, et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol. 2007;211:431–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Ruan WJ, Lin J, Xu EP, et al. IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B. 2006;7:929–32.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Sprenger CC, Damon SE, Hwa V, et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res. 1999;59:2370–5.PubMedGoogle Scholar
  27. 27.
    Vizioli MG, Sensi M, Miranda C, et al. IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene. 2010;29:3835–44.CrossRefPubMedGoogle Scholar
  28. 28.
    Amemiya Y, Yang W, Benatar T, et al. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res Treat. 2011;126:373–84.CrossRefPubMedGoogle Scholar
  29. 29.
    Sprenger CC, Vail ME, Evans K, et al. Overexpression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene. 2002;21:140–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Benatar T, Yang W, Amemiya Y, et al. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res Treat. 2012;133:563–73.CrossRefPubMedGoogle Scholar
  31. 31.
    Seth A, Benatar T, Amemiya Y,et al. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Hugo J. 2010;4:110–1.Google Scholar
  32. 32.
    Sun HC, Qiu ZJ, Liu J, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol. 2007;30:1359–67.PubMedGoogle Scholar
  33. 33.
    Stanton KJ, Sidner RA, Miller GA, et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg. 2003;186:486–92.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Long Liu
    • 1
  • Zhihui Yang
    • 2
  • Weixing Zhang
    • 3
  • Bing Yan
    • 4
  • Qunhao Gu
    • 5
  • Jianpeng Jiao
    • 4
  • Xiaoqiang Yue
    • 1
  1. 1.Department of Traditional Chinese Medicine, Changhai HospitalSecond Military Medical UniversityShanghaiChina
  2. 2.Department of Pathologythe 81th Hospital of PLANanjingChina
  3. 3.Department of Traditional Chinese MedicineLishui HospitalZhejiangChina
  4. 4.Department of Traditional Chinese Medicine, Changzheng HospitalSecond Military Medical UniversityShanghaiChina
  5. 5.Department of General Surgery, Yueyang HospitalShanghai University of Traditional Chinese MedicineShanghaiChina

Personalised recommendations